Actively Recruiting
Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema
Led by University Hospital, Toulouse · Updated on 2025-12-31
60
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.
CONDITIONS
Official Title
Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary lymphedema or secondary lymphedema after breast cancer treatment
- Male and female aged 18 to 75 years
- Affiliated with a social security scheme in France
- Signed informed consent before participation and procedures
- No cancer recurrence for more than 3 years after surgery
- Body Mass Index less than 35
- Enrolled in a medical and educational care program for lymphedema
- Wearing a compression orthosis on the affected limb
You will not qualify if you...
- Active or strongly suspected bacterial or fungal infection
- Venous insufficiency in the limb with lymphedema
- History of deep venous thrombosis in the affected limb
- History of chronic inflammatory disease
- Active cancer during study management
- Participation in another therapeutic trial
- Pregnant or breastfeeding women
- Metastatic cancer
- Bilateral breast cancer
- Obliterative arterial disease
- Multiple episodes of erysipelas
- Active smoking status
- Use of medications that delay healing (corticosteroids, immunosuppressants)
- Use of blood-thinning medications (aspirin, antiplatelet agents, anticoagulants)
- Allergy to Betadine
- Under guardianship, trusteeship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Toulouse Hospital
Toulouse, France
Actively Recruiting
Research Team
J
Julie MALLOIZEL-DELAUNAY, MD
CONTACT
C
Charline DAGUZAN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here